METTL14 Antibody [A8N22] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat, Monkey

Lane 1: NCCIT, Lane 2: F9, Lane 3: COS-7

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Human, Mouse, Rat, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
65 kDa

Datasheet & SDS

Biological Description

Specificity
METTL14 Antibody [A8N22] detects endogenous levels of total METTL14 protein.

Clone
A8N22

Synonym(s)
N(6)-adenosine-methyltransferase non-catalytic subunit METTL14;Methyltransferase-like protein 14;hMETTL14;METTL14;KIAA1627

Background
Methyltransferase‑like protein 3 (METTL3) is the catalytic core of an N6‑adenosine methyltransferase complex that installs m6A marks on a broad spectrum of RNA transcripts, where it functions as a key writer of the epitranscriptomic code that influences mRNA splicing, processing, translation efficiency, stability, and primary miRNA maturation. METTL3 directly catalyzes the transfer of methyl groups to adenosine residues, whereas its partner METTL14 acts as an RNA‑binding scaffold that helps position the substrate and stabilize the active conformation of the methyltransferase module, so that together they define the substrate specificity and methylation landscape of the complex. The complex is further regulated by the Wilms’ tumor 1‑associating protein (WTAP), which directs the METTL3–METTL14 core to nuclear speckles, specialized subnuclear domains enriched in splicing factors and RNA‑processing machinery, thereby coupling m6A deposition to cotranscriptional and early post‑transcriptional regulation. Through these mechanisms, METTL3‑dependent m6A modification modulates the expression of genes involved in circadian rhythm, embryonic stem cell self‑renewal, immune tolerance, meiotic progression, and fertility, underscoring its role in integrating transcriptional and post‑transcriptional control across diverse developmental and homeostatic pathways. METTL3 is frequently overexpressed in lung adenocarcinoma and other malignancies, where it enhances tumor‑cell growth, survival, and invasion by stabilizing or promoting the translation of oncogenic transcripts and by altering the abundance and activity of key signaling and metabolic regulators.

Background

Methyltransferase‑like protein 3 (METTL3) is the catalytic core of an N6‑adenosine methyltransferase complex that installs m6A marks on a broad spectrum of RNA transcripts, where it functions as a key writer of the epitranscriptomic code that influences mRNA splicing, processing, translation efficiency, stability, and primary miRNA maturation. METTL3 directly catalyzes the transfer of methyl groups to adenosine residues, whereas its partner METTL14 acts as an RNA‑binding scaffold that helps position the substrate and stabilize the active conformation of the methyltransferase module, so that together they define the substrate specificity and methylation landscape of the complex. The complex is further regulated by the Wilms’ tumor 1‑associating protein (WTAP), which directs the METTL3–METTL14 core to nuclear speckles, specialized subnuclear domains enriched in splicing factors and RNA‑processing machinery, thereby coupling m6A deposition to cotranscriptional and early post‑transcriptional regulation. Through these mechanisms, METTL3‑dependent m6A modification modulates the expression of genes involved in circadian rhythm, embryonic stem cell self‑renewal, immune tolerance, meiotic progression, and fertility, underscoring its role in integrating transcriptional and post‑transcriptional control across diverse developmental and homeostatic pathways. METTL3 is frequently overexpressed in lung adenocarcinoma and other malignancies, where it enhances tumor‑cell growth, survival, and invasion by stabilizing or promoting the translation of oncogenic transcripts and by altering the abundance and activity of key signaling and metabolic regulators.

References
https://pubmed.ncbi.nlm.nih.gov/34996469/ https://pubmed.ncbi.nlm.nih.gov/41139780/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%